EO-2463

Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL) $9 million from new investor The Institute for Follicular Lymphoma Innovation (IFLI) $10 million from existing specialist investors, including The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) June 12, 2025 Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing to advance its lead clinical program EO2463 OncoMimics™ immunotherapy to treat indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and finalize the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial. New U.S. investor The Institute for Follicular Lymphoma Innovation (IFLI), a global non-profit foundation dedicated to advancing research and treatment for follicular lymphoma, invested $9 million in the round, of which $5 million will be allocated to Enterome upon closing and an additional $4 million in conditional tranched funding. Existing shareholders invested an additional $10 million including: SymBiosis, a U.S. venture capital firm; Seventure Partners, based in France; Lundbeckfonden BioCapital from Denmark; Primo Capital, an Italian venture capital and private equity firm; and The U.S. Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP). “Attracting highly specialized blood cancer investor IFLI to this financing demonstrates the conviction of our new and existing investors in the potential of OncoMimics™ for blood and solid tumor cancers,” said Pierre Bélichard, Enterome’s Chief Executive Officer. “We currently are generating exciting clinical proof of concept data for EO2463 monotherapy in several iNHL patient populations included in the Phase 1/2 SIDNEY clinical trial. Most importantly, EO2463 has shown robust clinical efficacy and exceptional safety and tolerability – which is especially impressive for such a potent immunotherapy. This offers a new hope for these patients and a rare opportunity to create an entirely new market segment for an impactful therapeutic. This financing will enable us to continue the SIDNEY trial of EO2463 and prepare to launch a first pivotal Phase 3 trial of this candidate for the ‘watch-and-wait’ iNHL population.” The company presented interim SIDNEY dataat the American Society of Hematology (ASH) conference in December 2024, showing highly encouraging responses in the Cohort 2 of “watch and wait” iNHL patients in the ongoing SIDNEY study. This population, as the name suggests, is generally not eligible to receive other treatments due to the unacceptable risk-benefit ratio (in this iNHL sub-population) of the most commonly used blood cancer therapies. The company also recently disclosed having held positive meetings with both FDA (Type C meeting) and EMA (Scientific Advice), outlining a clear regulatory path registration for marketing authorizations in “watch-and-wait” iNHL. “This investment aligns with IFLI’s mission to accelerate the development of innovative therapies and precision biomarkers for follicular lymphoma,” said Michel Azoulay, MD, Chief Medical Officer at IFLI. “EO2463 represents a novel class of synthetic, off-the-shelf Immunotherapeutics with a unique mechanism of action that selectively targets malignant B cells. We are particularly interested in supporting Enterome’s efforts to demonstrate EO2463’s clinical efficacy across multiple lines of therapy, including in relapsed and refractory settings.” Enterome recently announced that it will present new data showing EO2463 also has a meaningful impact when tested in combination with standard of care in relapsed and refractory iNHL patients at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21. Previous findings presented at ASCO in 2024 in the relapsed and refractory patient population further suggested the potential to identify individuals most likely to benefit from EO2463 treatment, supported by biomarker analyses. Lore Gruenbaum, Chief Scientific Officer at LLS, said, “It is important for us to continue to support Enterome, a company working to develop novel therapeutics based on our shared commitment to create better therapies for blood cancers. LLS has invested over $1.8 billion in groundbreaking research since our inception in 1949. Our active partnership with Enterome, through our Therapy Acceleration Program, will continue to advance the clinical development of the OncoMimics™ family of novel immunotherapeutics for the benefit of blood cancer patients. We are particularly excited to help advance EO2463 which has shown promising signs of efficacy as monotherapy with excellent safety and tolerability in ‘watch-and-wait’ iNHL patients, who currently have no approved treatment options.” EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimics™ peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that mimic the B lymphocyte-specific lineage markers CD20, CD22, CD37, and CD268 (BAFF receptor). EO2463 also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2). The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes. By ensuring broad target coverage across malignant B cells, this novel approach aims to simultaneously improve safety and maximize efficacy, reducing the tumor cells’ capacity to develop immune-resistance mechanisms such as antigen escape. SIDNEY is an ongoing 12-month open label Phase 1/2 study that aims to assess safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy in up to about 55 patients with follicular lymphoma and marginal zone lymphoma including divided into three cohorts: newly diagnosed patients eligible to watch-and-wait (monotherapy); newly diagnosed patients in need of therapy / first line (combo with rituximab); patients with relapsed/refractory disease (combo with R2). In addition to safety, survival, response rates and other measures of efficacy are being collected. OncoMimics™ were inspired by the microbial origin of certain autoimmune diseases. The Company uses AI and machine learning to identify microbial proteins that closely mimic the structure, effect or actions of specific cancer antigens (as well as hormones or cytokines). Memory T cells against microbial antigen are created during early development, sometimes leading to autoimmune disorders. In the case of OncoMimics™, however, this means that the immune system can mount a rapid, robust and durable immune response that is highly targeted and specific for the OncoMimics™ and the cancer antigens they closely resemble. This is possible because, unlike cancer antigens, OncoMimics™ bypass the biological process, known as thymic deletion, that prevents the immune system from mounting an attack against the “self” proteins (e.g. antigen) on tumor and blood cancer cells. Once activated, the immune system attacks with high specificity and potency the cancer antigens targeted by the OncoMimics™, killing the cancer cells that carry them. OncoMimics™ are synthetic peptides that are easy to manufacture, store, distribute and administer as an off-the-shelf subcutaneous injection. In clinical testing to date they have been shown to be extremely well tolerated, especially compared to other potent immunotherapies. Enterome SA (www.enterome.com) is a privately held clinical-stage biopharmaceutical company developing OncoMimics™, a new proprietary immunotherapeutic modality inspired by the microbial origin of certain autoimmune diseases, to treat cancer. The Company’s wholly-owned OncoMimics™ pipeline includes three distinct clinical-stage drug candidates: EO2463 to treat indolent non-Hodgkin lymphomas; EO4010 to treat third-line colorectal cancer; and EO2401 to treat glioblastoma and adrenal tumors. Each of these candidates has shown positive early clinical efficacy and exceptional safety and tolerability. The content above comes from the network. if any infringement, please contact us to modify.

根据公开信息，上周（6月9日~6月15日），全球范围内有至少7家致力于创新药研发的新锐公司宣布完成新一轮融资。通过梳理，这些获得资本青睐的新锐公司正在开发的产品包括放射性药物、多肽、基因治疗药物、小分子药物等等，聚焦的疾病领域涵盖了癌症、抑郁症等神经系统疾病、阻塞性睡眠呼吸暂停（OSA）等。景嘉航融资轮次：天使轮融资金额：数千万元6月13日，杭州景嘉航生物医药科技有限公司（AB-RayBio Therapeutics，简称“景嘉航”）完成数千万元人民币的天使轮融资。本轮融资由杭实资管领投，正景资本和滨江伍零伍零跟投，所募资金将主要用于公司现有管线的临床前和早期临床开发。景嘉航成立于2024年5月，是一家处于临床研究阶段的创新药公司，聚焦新型的靶向放射性药物的研发。该公司专注攻克癌症等重大疾病，旨在为临床提供精准诊断与靶向治疗的诊疗一体化解决方案。景嘉航目前拥有8条在研管线，其中JJH002管线数据优异，已经处于IIT阶段和IND申请准备阶段。Enterome融资轮次：未披露融资金额：1900万美元6月12日，Enterome公司宣布通过新一轮私募融资筹集1900万美元，以推进其治疗惰性非霍奇金淋巴瘤（iNHL）的主导临床项目EO2463 OncoMimics免疫疗法。新资金将用于扩大并完成正在进行的EO2463 1/2期SIDNEY临床试验，并为该候选药物的注册试验做准备。EO2463是一种创新型即用型免疫治疗候选药物，由4种模拟B细胞肿瘤相关抗原CD20、CD22，CD37和CD268（BAFF受体）的多肽以及辅助性的UCP2肽组成，能够激活抗肿瘤免疫反应，清除癌变B细胞。Enterome公司的OncoMimics管线包含三个临床阶段候选药物：治疗惰性非霍奇金淋巴瘤的EO2463；治疗三线结直肠癌的EO4010；治疗胶质母细胞瘤和肾上腺肿瘤的EO2401。这些候选药物均显示出积极的早期临床疗效及安全性和耐受性。因诺惟康融资轮次：A+轮融资金额：数千万元6月12日，北京因诺惟康医药科技有限公司（简称“因诺惟康”，InnoVec Biotherapeutics）宣布完成数千万元的A+轮融资，本轮投资由天创资本领投，新投资人及老股东跟投。所募集的资金将主要用于公司产品管线的临床验证和推进以及基因递送平台的创新。因诺惟康是一家以载体创新为驱动的临床阶段基因治疗公司，致力于开发适用于人体的基因治疗递送工具，使基因治疗能够广泛应用到罕见疾病和常见疾病当中。因诺惟康聚焦眼科，神经和肌肉等多个疾病领域，多个创新产品已经进入IIT和IND阶段。Elkedonia融资轮次：种子轮融资金额：1125万欧元6月11日，Elkedonia宣布超额完成1125万欧元种子轮融资。本轮融资由Kurma Partners、WE Life Sciences和French Tech Seed基金共同领投，Argobio、Angelini Ventures、CARMA Fund、Capital Grand Est及Sambrinvest参与投资。Elkedonia公司聚焦新型细胞内靶点Elk1——该蛋白在奖赏脑回路和神经可塑性中起关键作用，而这些机制在抑郁症、创伤后应激障碍（PTSD）和成瘾等疾病中发生异常。Elkedonia正在开发一种神经可塑性药物，旨在恢复神经可塑性且不产生致幻剂或氯胺酮衍生物的副作用。临床前和临床研究证据表明，抑制Elk1是实现抑郁症快速治疗的有效途径，且无镇静、依赖、致幻等现有抗抑郁疗法常见副作用。Antares Therapeutics融资轮次：A轮融资金额：1.77亿美元6月10日，Antares Therapeutics宣布启动1.77亿美元A轮融资。本轮融资由Omega Funds、Atlas Venture、Lightspeed Venture Partners、BVF Partners和Cormorant Asset Management共同领投，Vinyanshu Ventures、Abingworth、Invus、Tenmile、Vida Ventures及Willett Advisors参与投资。Antares是Scorpion Therapeutics的分拆公司，后者于2025年3月将其突变选择性PI3Kα抑制剂项目STX-478以最高25亿美元总对价授权给礼来公司（Eli Lilly and Company），且五年间累计融资4.2亿美元，与多家药企达成合作，并产生6个开发候选药物，其中3个已进入临床测试。Antares正在推进包括精准肿瘤学和其他治疗领域在内的小分子资产管线，该公司还宣布与皮尔法伯（Pierre Fabre ）达成协议，后者获得两个临床阶段高选择性新一代突变EGFR抑制剂（用于治疗非小细胞肺癌）的全球权益。32 Biosciences融资轮次：未披露融资金额：600万美元6月10日，32 Biosciences宣布获得600万美元融资，用于支持其主导资产的持续开发。该公司的治疗性创新产品是一种非抗生素类抗菌剂，通过抑制毒力基因表达、增强肠道黏膜屏障及促进有益菌生长来预防肠道源性细菌感染。该疗法有望在不导致抗生素耐药性的前提下显著降低感染率及感染相关死亡率。Mosanna Therapeutics融资轮次：A轮融资金额：8000万美元6月9日，临床阶段生物技术公司Mosanna Therapeutics宣布完成8000万美元A轮融资。该公司正在开发一种夜间使用的便捷鼻喷剂，旨在通过恢复人体自然气道调控功能，治疗阻塞性睡眠呼吸暂停（OSA）。本轮融资由EQT生命科学和Pivotal bioVenture Partners领投，Forbion、Broadview Ventures及Norwest共同领投，创始投资者Forty51 Ventures以及Supermoon Capital、High-Tech Gründerfonds（HTGF）跟投。MOS118的作用机制是通过靶向维持气道通畅的上呼吸道肌肉，恢复患者夜间减弱的自然气道反射功能。新闻稿介绍，Mosanna的突破性在于将睡眠呼吸暂停视为神经肌肉功能障碍而非单纯机械问题，MOS118有望成为首个通过鼻喷形式恢复人体自然气道反射的疗法，有望显著提升长期缺乏有效治疗手段的患者依从性和治疗效果。期待在资本的助力下，更多前沿疗法和技术能够更快惠及患者。参考资料：[1]各公司官网及公开资料版权说明：本文欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权或其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。